Table 3.
Univariable and multivariable Cox proportional hazards models with 7 and 21-day landmark times applied to the cohort and a maximum 14-day observation period. HRs and presented with 95% CIs. Results that are statistically significant at the 95% level are highlighted in bold font
| 7-day landmark, 14-day observation | 21-day landmark, 14-day observation | |||
|---|---|---|---|---|
| HRs (95% CI) | Univariable | Multivariable | Univariable | Multivariable |
| Age | 0.998 (0.97, 1.025) | 1.005 (0.977, 1.034) | 1.012 (0.963, 1.064) | 1.014 (0.963, 1.068) |
| Previous positive PCR test (reference: no) | ||||
| Yes | 0.549 (0.273, 1.102) | 0.435 (0.215, 0.881) | 0.808 (0.276, 2.364) | 0.693 (0.233, 2.055) |
| Sex (reference: female) | ||||
| Male | 1.526 (0.952, 2.446) | 1.584 (0.969, 2.589) | 1.025 (0.425, 2.471) | 0.995 (0.402, 2.462) |
| HFRS (reference: no score) | ||||
| Low | 1.047 (0.438, 2.505) | 1.04 (0.434, 2.49) | 2.247 (0.436, 11.58) | 2.307 (0.447, 11.911) |
| Intermediate | 1.136 (0.631, 2.045) | 1.226 (0.679, 2.216) | 4.251 (1.453, 12.436) | 4.479 (1.523, 13.169) |
| High | 1.027 (0.576, 1.829) | 1.095 (0.612, 1.958) | 2.528 (0.802, 7.967) | 2.653 (0.838, 8.401) |
| Vaccine (reference: Oxford–Astrazeneca) | ||||
| Pfizer-BioNTECH | 3.78 (2.307, 6.194) | 4.316 (2.616, 7.121) | 1.646 (0.563, 4.817) | 1.917 (0.647, 5.682) |
| Observations | 13,989 | 13,989 | 13,605 | 13,605 |
| Events | 73 | 73 | 24 | 24 |
| Concordance (Standard Error) | 0.684 (s.e. 0.032) | 0.681 (s.e. 0.056) | ||
| Global Schoenfeld residual | ||||
| Chi-squared | 6.2 | 14.5 | ||
| Degrees of freedom | 7 | 7 | ||
| P value | 0.51 | 0.04 | ||